Denufosol patents and clinical trials: Drug pipeline profiles for drugs in development

Title	Sponsor	Phase
A Safety and Tolerability Study of Denufosol in 2-4 Year Olds	Merck Sharp & Dohme Corp.	Phase 2
Study 08-114 Open-label Extension of Study 08-110 - A Multi-Center Study of Denufosol Tetrasodium Inhalation Solution in Patients With Cystic Fibrosis Lung Disease (P08642)	Merck Sharp & Dohme Corp.	Phase 3
Study of Denufosol Tetrasodium Inhalation Solution in Patients With Cystic Fibrosis (CF) Lung Disease	Merck Sharp & Dohme Corp.	Phase 3

Subscribe to access the full database, or Start Trial
Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration
>Drugname	>Patent Number	>Patent Title	>Patent Assignee	>Estimated Expiration

Last updated: September 13, 2026

Denufosol is a discontinued inhaled cystic-fibrosis drug candidate that did not demonstrate sufficient efficacy in a Phase 3 trial. It was never approved by the FDA or marketed commercially. Its current addressable market is therefore zero, and a conventional launch forecast is not supportable without a new sponsor, new clinical program, and new regulatory strategy.

What is denufosol and how was it intended to work?

Denufosol, also known as denufosol tetrasodium and INS37217, was an inhaled P2Y2-purinergic receptor agonist developed for cystic fibrosis.

The candidate was designed to improve mucociliary clearance through several mechanisms:

Increasing chloride and fluid secretion across airway epithelium
Stimulating ciliary beat frequency
Improving hydration of airway surface liquid
Supporting clearance of mucus independent of the cystic-fibrosis transmembrane conductance regulator, or CFTR, protein

That mechanism was commercially relevant because denufosol was intended to work across different CFTR mutation classes. Unlike CFTR modulators, it did not require a responsive CFTR protein.

Denufosol was administered as an inhaled solution through a nebulizer. It was positioned as a chronic maintenance treatment rather than an antibiotic or acute rescue therapy.

What was the development history of denufosol?

Inspire Pharmaceuticals advanced denufosol through early and mid-stage clinical testing in cystic fibrosis. The program generated encouraging signals in earlier studies, including an improvement in lung-function measures in some patient groups. Those results supported development of a larger Phase 3 program.

The principal late-stage study was TIGER-1, a randomized, controlled trial evaluating inhaled denufosol in patients with cystic fibrosis. The study assessed lung-function change, primarily forced expiratory volume in one second, or FEV1.

Denufosol development timeline

Period	Development event	Commercial significance
Early 2000s	Preclinical and early clinical development by Inspire Pharmaceuticals	Established the P2Y2 agonist mechanism
Mid-2000s	Phase 2 cystic-fibrosis studies	Produced sufficient efficacy signals for late-stage testing
2008	TIGER-1 Phase 3 trial initiated	Formal registration-oriented development began
2010	TIGER-1 failed its primary efficacy endpoint	Regulatory approval path was materially weakened
2010-2011	Development program was discontinued or no longer advanced	Denufosol ceased to be a viable near-term commercial product
Present	No FDA approval or commercial launch	No marketed denufosol revenue

ClinicalTrials.gov identified TIGER-1 as a Phase 3 study of denufosol inhalation solution in cystic fibrosis. The study was designed to evaluate pulmonary function over a controlled treatment period (ClinicalTrials.gov, n.d.).

Why did denufosol fail in Phase 3?

The central development problem was failure to reproduce the earlier efficacy signal at the scale and rigor required for registration.

TIGER-1 did not meet its primary endpoint for improvement in lung function. The result limited the ability of Inspire Pharmaceuticals to demonstrate a clinically meaningful benefit over standard care. In cystic fibrosis, a development program must usually show durable improvement in validated pulmonary outcomes, reduction in pulmonary exacerbations, or another clinically relevant benefit that supports chronic use.

The failure had several commercial consequences:

The original efficacy thesis was not confirmed in a pivotal population.
A confirmatory trial or major protocol redesign would have required substantial additional capital.
The product faced competition from established inhaled therapies and an emerging CFTR-modulator class.
The nebulized delivery format created treatment-burden concerns.
The clinical value proposition was weaker if denufosol could not demonstrate a measurable benefit beyond existing airway-clearance therapies.

The failure did not establish that P2Y2 agonism was biologically inactive. It showed that the specific denufosol development package did not produce sufficient clinical evidence for approval.

What is the FDA regulatory status of denufosol?

Denufosol has no FDA approval for cystic fibrosis or any other indication.

The product therefore has:

No approved prescribing information
No FDA-labeled indication
No commercial National Drug Code product
No Orange Book listing
No approved pediatric or adult dosing regimen
No established reimbursement category as a marketed medicine

Because denufosol was never approved, it does not have FDA regulatory exclusivity comparable to new chemical entity exclusivity, orphan-drug exclusivity, or pediatric exclusivity attached to an approved product.

What is the Orange Book status of denufosol?

Denufosol is not an Orange Book-listed drug. The Orange Book lists approved drug products and associated patent and exclusivity information. An investigational product that never received FDA approval does not receive an Orange Book listing.

The absence of an Orange Book entry means there is no conventional abbreviated new drug application, or ANDA, pathway based on an approved denufosol reference product. A future developer would need to pursue a new drug application or another applicable regulatory route rather than rely on an ordinary generic substitution model.

Are there Paragraph IV challenges to denufosol?

No commercially relevant Paragraph IV challenge exists for denufosol.

Paragraph IV litigation normally arises when a generic applicant certifies that a listed patent for an approved reference drug is invalid, unenforceable, or will not be infringed. Denufosol has no approved reference product and no Orange Book patent listing. As a result:

No ANDA-based Paragraph IV litigation is expected.
No 30-month stay framework applies to a denufosol generic.
No first-filer generic exclusivity is associated with denufosol.
Any future competitor would be pursuing a new development and approval strategy, not a conventional generic launch.

What patents protected denufosol?

Denufosol was developed under an intellectual-property portfolio covering the active compound, purinergic receptor agonist activity, inhaled formulations, and methods for treating respiratory disease.

The commercial value of that portfolio has declined for two reasons. First, the clinical program failed before approval. Second, the relevant patent terms have aged substantially since the principal development period in the 2000s.

A patent portfolio can retain technical value after clinical discontinuation, but it does not create a viable market without:

A sponsor willing to restart development
A defensible clinical differentiation strategy
Remaining patent term or new patentable improvements
Manufacturing and formulation control
Evidence that the product can outperform current CF treatment

There is no active commercial denufosol patent barrier comparable to the patent estates surrounding approved CFTR modulators. Nor is there an active branded product against which a generic manufacturer must time entry.

Does denufosol face biosimilar or generic competition?

Denufosol does not face biosimilar competition because it is a small-molecule investigational drug, not a biologic.

It also does not face ordinary generic competition because no denufosol reference product was approved and marketed. A future entrant would need to develop and obtain approval for its own product. The primary barrier would be clinical and regulatory validation, not substitution against a currently sold brand.

Competitive comparison with approved cystic-fibrosis therapies

Product class	Representative products	Regulatory status	Competitive position versus denufosol
CFTR modulators	Ivacaftor, lumacaftor/ivacaftor, tezacaftor/ivacaftor, elexacaftor/tezacaftor/ivacaftor	FDA approved for defined mutation groups	Disease-modifying efficacy and strong commercial adoption
Inhaled antibiotics	Tobramycin, aztreonam lysine, levofloxacin in some markets	Approved for chronic pulmonary infection indications	Treat infectious complications rather than mucus clearance
Hypertonic saline	Nebulized formulations	Widely used supportive therapy	Low-cost airway-clearance alternative
Dornase alfa	Pulmozyme	FDA approved	Established mucus-thinning therapy
Denufosol	INS37217	Never approved	No current commercial position

CFTR modulators significantly changed the treatment landscape after denufosol’s late-stage development. These agents offered mutation-targeted treatment and, in the case of highly effective triple therapy, materially stronger clinical and commercial differentiation than a nonspecific airway-clearance agent.

What is the current development status of denufosol?

Denufosol is inactive as a commercial development program.

There is no evidence of:

An active Phase 3 denufosol trial
A current FDA review
A new drug application
A marketed product
A current commercial sponsor advancing denufosol
A clinical program designed to revive the original asset

In practical terms, denufosol should be classified as discontinued, not delayed. A restart would require a new sponsor to establish a contemporary development rationale and generate new clinical evidence.

What is the market projection for denufosol?

The base-case market projection is zero revenue through the foreseeable forecast period because denufosol has no approval, no active sponsor, and no commercial supply.

Market projection scenarios

Scenario	Probability assessment	Revenue outlook	Required conditions
Base case: permanent discontinuation	Highest	$0	No further development
Asset revival by a new sponsor	Low	Unquantifiable	New clinical program, funding, manufacturing, and regulatory engagement
Approval for cystic fibrosis	Very low	Potentially modest to meaningful, depending on differentiation	Positive efficacy trial and clear benefit over current care
Repurposing in another respiratory indication	Very low	Unquantifiable	New indication-specific clinical evidence
Generic or biosimilar entry	Not applicable	$0	No approved reference product exists

A hypothetical approved market would also be smaller than the original opportunity implied by the cystic-fibrosis patient population. Modern CF treatment is increasingly stratified by genotype, age, disease severity, and prior use of CFTR modulators. A new inhaled maintenance product would need to show benefit in patients who are not adequately controlled with modulators or who cannot use them.

The product would also compete with low-cost airway-clearance therapies, inhaled mucolytics, antibiotics, and established nebulized treatment routines. Without a measurable reduction in exacerbations, treatment burden, or decline in lung function, pricing power would be limited.

What commercial barriers would a denufosol revival face?

A revived denufosol program would encounter several barriers.

Clinical differentiation

The product would need to demonstrate clinically meaningful benefit in the current standard-of-care environment. Improvement in a surrogate lung-function endpoint alone might not support premium pricing if patients already receive highly effective CFTR-modulator therapy.

Delivery and adherence

Denufosol’s nebulized administration adds time and equipment requirements. Patients with cystic fibrosis often use several inhaled therapies daily. A new nebulized medicine would need to reduce treatment burden or deliver a clear incremental benefit.

Manufacturing

The active pharmaceutical ingredient and inhaled solution would require validated sterile manufacturing, container-closure controls, nebulizer compatibility, and stability data. Device performance would also form part of the regulatory package.

Reimbursement

Payers would likely demand evidence of reduced exacerbations, hospitalization, antibiotic use, or pulmonary decline before granting broad coverage. A product with only modest FEV1 improvement would face formulary pressure.

Intellectual property

Older composition and use patents would provide less protection because of patent-term erosion. A restart would likely depend on new patents covering formulation, device performance, dosing, combination use, or a newly defined patient population.

What is the investment and licensing outlook for denufosol?

Denufosol has limited standalone licensing value. The asset lacks the characteristics typically required for a near-term pharmaceutical transaction:

No approval
No active pivotal program
No current revenue
No established market access
No confirmed clinical differentiation
No clear exclusivity runway tied to an approved product

Potential value would be option-like rather than revenue-based. A buyer would be acquiring historical clinical data, know-how, patents with potentially limited remaining term, and the possibility of rebuilding the program. The transaction would be more consistent with an early-stage or distressed asset acquisition than a late-stage licensing deal.

Key Takeaways

Denufosol was an inhaled P2Y2 receptor agonist developed by Inspire Pharmaceuticals for cystic fibrosis.
The Phase 3 TIGER-1 study failed to meet its primary lung-function endpoint.
Denufosol was never approved by the FDA and has no Orange Book listing.
There is no conventional Paragraph IV, generic, or biosimilar threat.
The program is discontinued, with no active commercial development identified.
Its current market revenue is effectively zero.
A future revival would require a new sponsor, new clinical evidence, a modern competitive strategy, and likely new formulation or delivery patents.
CFTR modulators and established inhaled therapies have materially reduced the commercial attractiveness of the original denufosol proposition.

FAQs

Is denufosol still being developed for cystic fibrosis?

No. Denufosol is not an active late-stage development program and has no current FDA review or marketed product.

Did denufosol receive orphan-drug approval?

No. Denufosol may have been developed for the orphan cystic-fibrosis population, but it never received FDA marketing approval or orphan-drug exclusivity attached to an approved product.

Can a generic company launch denufosol?

Not through a conventional ANDA substitution pathway. No approved reference product exists. A future developer would need to pursue its own regulatory approval.

Was denufosol replaced by CFTR modulators?

CFTR modulators did not formally replace denufosol, but they changed the competitive environment. Their disease-directed efficacy made it harder for a nonspecific mucus-clearance therapy to justify a separate premium product.

What would make denufosol commercially viable again?

A revival would require clear efficacy in a defined underserved CF population, a low-burden delivery system, meaningful effects on exacerbations or lung-function decline, workable manufacturing, and defensible new intellectual property.

References

ClinicalTrials.gov. (n.d.). A study of denufosol tetrasodium inhalation solution in subjects with cystic fibrosis: TIGER-1. U.S. National Library of Medicine.
U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
Inspire Pharmaceuticals, Inc. (2010). Inspire announces top-line results from Phase 3 TIGER-1 trial of denufosol inhalation solution in cystic fibrosis. Company announcement.
Knowles, M. R., Church, N. L., Waltz, D. A., Yankaskas, J. R., Gilligan, P., Yankaskas, J. R., ... & Boucher, R. C. (2006). Denufosol tetrasodium, a P2Y2 agonist, in cystic fibrosis. American Journal of Respiratory and Critical Care Medicine.
Cystic Fibrosis Foundation. (n.d.). Cystic fibrosis drug development pipeline. https://www.cff.org/initiatives/drug-development-pipeline

US Patents	0
International Patents	0
US Patent Applications	213
WIPO Patent Applications	70
Japanese Patent Applications	50
Clinical Trial Progress	Phase 3 (2006-07-01)
Vendors	9

Investigational Drug Information for Denufosol

What is the drug development status for Denufosol?

Summary for Denufosol

Recent Clinical Trials for Denufosol

Clinical Trial Summary for Denufosol

Top disease conditions for Denufosol

Top clinical trial sponsors for Denufosol

US Patents for Denufosol

Denufosol Development Update and Market Projection